JP2020503367A5 - - Google Patents

Download PDF

Info

Publication number
JP2020503367A5
JP2020503367A5 JP2019537254A JP2019537254A JP2020503367A5 JP 2020503367 A5 JP2020503367 A5 JP 2020503367A5 JP 2019537254 A JP2019537254 A JP 2019537254A JP 2019537254 A JP2019537254 A JP 2019537254A JP 2020503367 A5 JP2020503367 A5 JP 2020503367A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
pac1
receptor agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019537254A
Other languages
English (en)
Japanese (ja)
Other versions
JP7183164B2 (ja
JP2020503367A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/012405 external-priority patent/WO2018129200A2/en
Publication of JP2020503367A publication Critical patent/JP2020503367A/ja
Publication of JP2020503367A5 publication Critical patent/JP2020503367A5/ja
Application granted granted Critical
Publication of JP7183164B2 publication Critical patent/JP7183164B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019537254A 2017-01-05 2018-01-04 Ｐａｃ１受容体作動薬（ｍａｘｃａｐ）及びその用途 Active JP7183164B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762442906P 2017-01-05 2017-01-05
US62/442,906 2017-01-05
PCT/US2018/012405 WO2018129200A2 (en) 2017-01-05 2018-01-04 Pac1 receptor agonists (maxcaps) and uses thereof

Publications (3)

Publication Number Publication Date
JP2020503367A JP2020503367A (ja) 2020-01-30
JP2020503367A5 true JP2020503367A5 (https=) 2021-02-18
JP7183164B2 JP7183164B2 (ja) 2022-12-05

Family

ID=62791208

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019537254A Active JP7183164B2 (ja) 2017-01-05 2018-01-04 Ｐａｃ１受容体作動薬（ｍａｘｃａｐ）及びその用途

Country Status (8)

Country Link
US (2) US11186622B2 (https=)
EP (1) EP3565573B1 (https=)
JP (1) JP7183164B2 (https=)
CN (1) CN110300595A (https=)
AU (1) AU2018205458A1 (https=)
CA (1) CA3049212A1 (https=)
MX (1) MX2019008056A (https=)
WO (1) WO2018129200A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3565573B1 (en) 2017-01-05 2023-08-23 The Regents of The University of California Pac1 receptor agonists (maxcaps) and uses thereof
US10624944B2 (en) * 2017-06-19 2020-04-21 Creative Bio-Peptides Inc. Anti-inflammatory peptides for treating non-alcoholic steatohepatitis (NASH)
USRE50630E1 (en) 2017-10-31 2025-10-14 Creative BioPeptides, Inc. Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
CN110747163B (zh) * 2019-11-13 2021-06-11 暨南大学 一种提高人脂肪间充质干细胞成脂分化的方法及其专用培养基
US11510961B2 (en) 2019-12-19 2022-11-29 Creative Bio-Peptides, Inc. Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof
CN111110830B (zh) * 2020-02-18 2023-05-26 暨南大学 生物活性多肽pacap在制备提高肥胖男性生育力的药物中的应用
WO2024140994A1 (zh) * 2022-12-29 2024-07-04 杭州百懿生物药业有限公司 一种融合蛋白
KR102673860B1 (ko) * 2023-08-10 2024-06-12 (주)케어젠 안구 건조증의 개선 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496542A (en) 1981-03-30 1985-01-29 Usv Pharmaceutical Corporation N-substituted-amido-amino acids
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
EP0092227B1 (en) 1982-04-19 1988-07-27 Nissan Motor Co., Ltd. Method for controlling reduction ratio of continuously variable transmission with acceleration compensation
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
ATE66469T1 (de) 1985-01-14 1991-09-15 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
CH677886A5 (https=) 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
US5397772A (en) 1989-06-29 1995-03-14 The President And Fellows Of Harvard College Vasodilatory peptides from the salivary gland of the sand fly Lutzomyia longipalpis
US5480864A (en) 1993-08-06 1996-01-02 Shiseido Co., Ltd. Modified maxadilan protein, its preparation and use, and DNA encoding the protein
KR950007873A (ko) 1993-09-20 1995-04-15 후꾸하라 요시하루 생리 활성 물질 지속 방출형의 의약 제제
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
FR2730932B1 (fr) 1995-02-27 1997-04-04 Oreal Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie
US6462016B1 (en) 1995-10-06 2002-10-08 Shiseido Company, Ltd. Method for screening agonist or antagonist of the maxadilan receptor participating in vasodilating action, and compound found by the method
FR2742676B1 (fr) 1995-12-21 1998-02-06 Oreal Nanoemulsion transparente a base de tensioactifs silicones et utilisation en cosmetique ou en dermopharmacie
US6017533A (en) 1996-04-25 2000-01-25 Shiseido Company, Ltd. Peptides having specific affinity to pituitary adenylate cyclase activating polypeptide type 1 receptors
FR2755854B1 (fr) 1996-11-15 1998-12-24 Oreal Nanoemulsion a base de lipides amphiphiles non-ioniques et cationiques et utilisations
FR2760970B1 (fr) 1997-03-18 2000-03-10 Oreal Nanoemulsions a base de lipides amphiphiles non-ioniques et de silicones aminees et utilisations
PL345583A1 (en) 1998-07-20 2001-12-17 Sod Conseils Rech Applic Peptide analogues of pacap
FR2787026B1 (fr) 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters mixtes d'acide gras ou d'alcool gras, d'acide carboxylique et de glyceryle, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787027B1 (fr) 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters gras de sucre ou d'ethers gras de sucre et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787326B1 (fr) 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787325B1 (fr) 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de sorbitan oxyethylenes ou non oxyethylenes, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787728B1 (fr) 1998-12-23 2001-01-26 Oreal Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2787703B1 (fr) 1998-12-29 2001-01-26 Oreal Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788007B1 (fr) 1999-01-05 2001-02-09 Oreal Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788449B1 (fr) 1999-01-14 2001-02-16 Oreal Nanoemulsion a base de citrates d'alkylether, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2789076B1 (fr) 1999-02-02 2001-03-02 Synthelabo Derives de alpha-azacyclomethyl quinoleine, leur preparation et leur application en therapeutique
ES2235854T3 (es) 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
WO2001085100A2 (en) 2000-05-11 2001-11-15 The General Hospital Corporation Vasodilator-thrombolytic fusion proteins and conjugates
FR2811564B1 (fr) 2000-07-13 2002-12-27 Oreal Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
US20020182729A1 (en) * 2001-01-11 2002-12-05 Dicicco-Bloom Emanuel Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo
FR2819427B1 (fr) 2001-01-18 2003-04-11 Oreal Nanoemulsion translucide, son procede de fabrication et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
JP2006512401A (ja) 2001-06-05 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ナノエマルジョンワクチン
AU2003228050A1 (en) * 2002-05-03 2003-11-17 Neuronova Ab Therapeutic use of PACAP, Maxadilan, PACAP receptor agonist and/or ADCYAP1R1 in the treatment of CNS disorders
US7476393B2 (en) 2002-11-29 2009-01-13 L'oreal Process for the preparation of a cationic nanoemulsion, and cosmetic composition
US7928186B2 (en) 2006-08-02 2011-04-19 Phoenix Pharmaceuticals, Inc. Cell permeable bioactive peptide conjugates
CN101125882B (zh) * 2007-07-20 2010-10-13 暨南大学 重组pac1受体激动剂rmmax及其表达方法与应用
CA2738549A1 (en) 2008-09-25 2010-04-01 The Administrators Of The Tulane Educational Fund Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with anticancer agents
CA2779496A1 (en) 2009-11-02 2011-05-05 The Administrators Of The Tulane Educational Fund Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use
EP2533795A4 (en) 2010-02-05 2013-10-16 Univ Tulane USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGUE AS SUPPORTING TREATMENT WITH INHIBITORS OF CALCINEURIN OR INHIBITORS OF MTOR COMPLEXES
US9939449B2 (en) 2011-02-01 2018-04-10 The University Of Vermont And State Agricultural College Diagnostic and therapeutic methods and products related to anxiety disorders
US20160122406A1 (en) 2013-06-07 2016-05-05 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use
EP3565573B1 (en) 2017-01-05 2023-08-23 The Regents of The University of California Pac1 receptor agonists (maxcaps) and uses thereof

Similar Documents

Publication Publication Date Title
JP2020503367A5 (https=)
CN101578102B (zh) 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
JP5765813B2 (ja) 治療用ペプチドのポリマーコンジュゲート
US9023986B2 (en) Glucose-dependent insulinotropic peptide analogs
CN104302772A (zh) 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
ES2359850T3 (es) Péptidos con actividad agonista del receptor del neuropéptido-2 (y2r).
US20110136724A1 (en) Analogues of glucose-dependent insulinotropic polypeptide
JP2007531715A (ja) グリコール結合ｆｇｆ−２１化合物
KR20190062344A (ko) 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체
US20120289453A1 (en) Novel glp-1 compounds
WO2019085772A1 (zh) 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化
TW201103556A (en) GIP receptor-active glucagon compounds
US20070244041A1 (en) Peptide Yy Analogues
JP2011530509A (ja) Ｎ末端において修飾されたグルコース依存性インスリン分泌刺激ポリペプチド（ｇｉｐ）のアナログ
US20230241178A1 (en) Long acting glp-1/gip dual agonists
BR112014027345A2 (pt) análogos de peptídeo 2 semelhante ao glucagon (glp-2)
JP2013542715A5 (https=)
JP2019520314A (ja) 脂肪性肝疾患、高脂血症及び動脈硬化治療用のｇｌｐ−１ｒ／ｇｃｇｒデュアルアゴニストペプチド
CN102397558A (zh) Exendin-4类似物的定位聚乙二醇化修饰物及其用途
JP2018500385A5 (https=)
JP2023548945A5 (https=)
WO2019085773A1 (zh) 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗特发性肺间质纤维化
JP2025519475A5 (https=)
CN109134610B (zh) 一种肽类化合物、其应用及含其的组合物
WO2022111713A1 (zh) 一种含有二硫键且具有抑制丝氨酸蛋白酶活性的多肽、其衍生的杂交肽及其应用